Recommendations on hepatitis C screening for adults

CMAJ

Volumn 189, Issue 16, 2017, Pages E594-E604

  Grad, Roland ^a   Thombs, Brett D ^a   Tonelli, Marcello ^b   Bacchus, Maria ^b   Birtwhistle, Richard ^c   Klarenbach, Scott ^d   Singh, Harminder ^e   Dorais, Veronique ^f   Holmes, Nathalie M ^f   Martin, Wendy K ^f   Rodin, Rachel ^f   Jaramillo Garcia, Alejandra ^f  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; FEASIBILITY STUDY; HEALTH CARE COST; HEALTH EQUITY; HEMODIALYSIS; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LIVER FIBROSIS; MIXED INFECTION; PATIENT PREFERENCE; POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SCREENING TEST; SEXUAL TRANSMISSION; VIRUS TRANSMISSION; ADVISORY COMMITTEE; CANADA; MASS SCREENING; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; STANDARDS;

ADULT; ADVISORY COMMITTEES; CANADA; HEPATITIS C; HUMANS; MASS SCREENING; PREVENTIVE HEALTH SERVICES;

EID: 85018943124     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.161521     Document Type: Article

References (100)

1. Trubnikov M, Yan P, Archibald C. Estimated prevalence of hepatitis C virus infection in Canada, 2011. Can Commun Dis Rep. 2014;40. Available: www.phac-aspc. gc.ca/publicat/ccdr-rmtc/14vol40/dr-rm40-19/surveillance-b-eng.php (accessed 2017 Apr. 6).
2. Rotermann M, Langlois K, Andonov A, et al. Seroprevalence of hepatitis B and C virus infections: results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Cat no 82-003-X, Health Rep Vol 24, No 11;3-13. Ottawa: Statistics Canada; 2013. Available: www.statcan.gc.ca/pub/82-003-x/2013011/ article/11876-eng.pdf (accessed 2016 Nov. 1).
3. Healthy Canadians: risks of hepatitis C. Ottawa: Government of Canada; 2016. Available: https://www.canada.ca/en/public-health/services/diseases/ hepatitis -c/risks-hepatitis-c.html (accessed 2016 Nov. 1).
4. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009;29(Suppl 1):89-99.
5. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-31.
6. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61(Suppl):S58-68.
7. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52.
8. Innes HA, McDonald SA, Dillon JF, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 2015;62:355-64.
9. Recommendations: diagnosis of acute and chronic hepatitis C. Geneva: European Association for the Study of the Liver (EASL); 2015. Available: www.easl.eu/ research/our-contributions/clinical-practice-guidelines/detail/recommendations-on -treatment-of-hepatitis-c-2015/report/4 (accessed 2016 Oct. 18).
10. Wells G, Kelly S, Farah B, et al. Drugs for chronic hepatitis C infection: clinical review. CADTH Therapeutic Review, Vol 3. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2016. Available: https://www.cadth.ca/sites/default/files/pdf/TR0008-Clinical-Report-en.pdf (accessed 2016 Oct. 18).
11. Summary basis of decision for INCIVEK. Ottawa: Health Canada; 2012. Available: https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailOne. php?lang=en&linkID=SBD00070 (accessed 2017 Apr. 6).
12. Regulatory decision summary for EPCLUSA. Ottawa: Health Canada; 2016. Available: https://hpr-rps.hres.ca/reg-content/regulatory-decision-summary -detail.php?lang=en&linkID=RDS00181 (accessed 2017 Apr. 6).
13. Shah HA, Heathcote J, Feld JJ. A Canadian screening program for hepatitis C: is now the time? CMAJ 2013;185:1325-8.
14. Pinette G, Cox J, Heathcote J, et al. Primary care management of chronic hepatitis C: professional desk reference 2009. The College of Family Physicians of Canada (CFPC) and the Public Health Agency of Canada (PHAC); 2009. Available: www.cfpc.ca/uploadedFiles/Resources/Resource-Items/HEP-C-Guide-eng-2.pdf (accessed 2016 Nov. 3).
15. Canadian Task Force on Preventive Health Care. Canadian Task Force on Preventive Care procedure manual. Calgary; 2014. Available: http://canadiantaskforce .ca/methods/ (accessed 2017 Apr. 6).
16. Screening for hepatitis C: a systematic review and meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2016. Available: https://www. cadth.ca/screening-hepatitis-c-systematic-review-and-meta-analysis (accessed 2017 Feb. 27).
17. Reyes Domingo F, Holmes NM, Jaramillo Garcia A, et al. Treatment for hepatitis C virus: a systematic review and meta-analysis. Updated 7 April 2017. 2017. Available: http://canadiantaskforce.ca/guidelines/published-guidelines/hepatitis-c/.
18. Schunemann H, Brożek J, Guyatt G, et al., editors. GRADE handbook. The GRADE Working Group; 2013. Available: http://gdt.guidelinedevelopment.org/ app/handbook/handbook.html (accessed 2017 Apr. 6).
19. St. Michael's Hospital, Knowledge Translation Program, Li Ka Shing Knowledge Institute. CTFPHC patient preferences protocol, updated 26 Jan. 2015. http://canadiantaskforce.ca/methods (accessed 2017 Apr. 5).
20. Buckland D, Sayal R, Bashir N, et al. Patient preferences in considering hepatitis C screening and treatment outcomes: phase two. Toronto: Li Ka Shing Knowledge Institute, St. Michael's Hospital; 2016. Available: http://canadiantaskforce. ca/guidelines/published-guidelines/hepatitis-c/.
21. Wong W, Erman A, Krahn M. Model-based Projection of Health and Economic Effect of Screening Hepatitis C in Canada 2016 update - Final Report. November 22, 2016. Available: http://canadiantaskforce.ca/guidelines/publishedguidelines/hepatitis-c/.
22. Pottie K, Siu W, Duclos P, and the members of the World Health Organization Technical Consultation on Pain Migration (2016). New recommendations to prevent pain during immunizations. WHO Position Paper. 2015. Available: doi:10.1016/j.vaccine.2015.11.064.
23. Connor Gorber S, Singh H, Pottie K, et al. Process for guideline development by the reconstituted Canadian Task Force on Preventive Health Care. CMAJ 2012;184:1575-81.
24. SOGC Clinical Practice Guidelines. The reproductive care of women living with hepatitis C infection. Ottawa: The Society of Obstetricians and Gynaecologists of Canada; 2000. Available: https://sogc.org/wp-content/uploads/2013/01/ gui96ECPG0010wDisclaimer.pdf (accessed 2016 Dec. 15).
25. Groom H, Dieperink E, Nelson DB, et al. Outcomes of a hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol 2008;42:97-106.
26. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(Suppl 1):S35-46.
27. Wong WW, Tu HA, Feld JJ, et al. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ 2015;187:E110-21.
28. Koretz RL, Lin KW, Ioannidis JPA, et al. Is widespread screening for hepatitis C justified? BMJ 2015;350:g7809.
29. Lyons MS, Kunnathur VA, Rouster SD, et al. Prevalence of diagnosed and undiagnosed hepatitis C in a midwestern urban emergency department. Clin Infect Dis 2016;62:1066-71.
30. Blaxhult A, Samuelson A, Ask R, et al. Limited spread of hepatitis C among HIVnegative men who have sex with men in Stockholm, Sweden. Int J STD AIDS 2014;25:493-5.
31. Sommese L, Sabia C, Paolillo R, et al. Screening tests for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus in blood donors: evaluation of two chemiluminescent immunoassay systems. Scand J Infect Dis 2014; 46:660-4.
32. Sommese L, Iannone C, Cacciatore F, et al. Comparison between screening and confirmatory serological assays in blood donors in a region of South Italy. J Clin Lab Anal 2014;28:198-203.
33. Valois RC, Maradei-Pereira LM, Crescente JA, et al. HCV infection through perforating and cutting material among candidates for blood donation in Belem, Brazilian Amazon. Rev Inst Med Trop Sao Paulo 2014;56:511-5.
34. Baha W, Foullous A, Dersi N, et al. Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. BMC Public Health 2013;13:50.
35. Zeba MT, Sanou M, Bisseye C, et al. Characterisation of hepatitis C virus genotype among blood donors at the regional blood transfusion centre of Ouagadougou, Burkina Faso. Blood Transfus 2014;12(Suppl 1):s54-7.
36. Li D, Long Y, Wang T, et al. Epidemiology of hepatitis C virus infection in highly endemic HBV areas in China. PLoS One 2013;8:e54815.
37. Martins T, Machado DF, Schuelter-Trevisol F, et al. Prevalence and factors associated with HCV infection among elderly individuals in a southern Brazilian city. Rev Soc Bras Med Trop 2013;46:281-7.
38. Woo GA, Hill MA, de Medina MD, et al. Screening for hepatitis B virus and hepatitis C virus at a community fair: a single-center experience. Gastroenterol Hepatol (N Y) 2013;9:293-9.
39. Kesli R, Polat H, Terzi Y, et al. Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results. J Clin Microbiol 2011;49:4089-93.
40. Kesli R, Ozdemir M, Kurtoglu MG, et al. Evaluation and comparison of three different anti-hepatitis C virus antibody tests based on chemiluminescence and enzyme-linked immunosorbent assay methods used in the diagnosis of hepatitis C infections in Turkey. J Int Med Res 2009;37:1420-9.
41. Rashdan A, Hijjawi S, Jadallah K, et al. Prevalence of hepatitis C virus antibodies among blood donors in Northern Jordan. Jordan Med J 2008;42:179-83.
42. Reis NRS, Motta-Castro ARC, Silva AMC, et al. Prevalence of hepatitis C virus infection in quilombo remnant communities in Central Brazil. Rev Inst Med Trop Sao Paulo 2008;50:359-60.
43. Slavenburg S, Verduyn-Lunel FM, Hermsen JT, et al. Prevalence of hepatitis C in the general population in the Netherlands. Neth J Med 2008;66:13-7.
44. Letowska M, Brojer E, Mikulska M, et al. Hepatitis C core antigen in Polish blood donors. Transfusion 2004;44:1067-71.
45. Dalgard O, Jeansson S, Skaug K, et al. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol 2003; 38:864-70.
46. Zervou EK, Boumba DS, Liaskos C, et al. Low prevalence of HCV, HIV, and HTLV-I/II infection markers in northwestern Greece: results of a 3-year prospective donor study (1995-1997). Eur J Intern Med 2003;14:39-44.
47. Alberti A, Noventa F, Benvegnu L, et al. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002;137:961-4.
48. Kondili LA, Chionne P, Costantino A, et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 2002;50:693-6.
49. Muerhoff AS, Jiang L, Shah DO, et al. Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay. Transfusion 2002;42:349-56.
50. Icardi G, Ansaldi F, Bruzzone BM, et al. Novel approach to reduce the hepatitis C virus (HCV) window period: Clinical evaluation of a new enzyme-linked immunosorbent assay for HCV core antigen. J Clin Microbiol 2001;39:3110-4.
51. Maio G, d'Argenio P, Stroffolini T, et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern italian town. J Hepatol 2000;33:116-20.
52. Lucas RE, Faoagali JL. The serological status of Solomon Island blood donors. Southeast Asian J Trop Med Public Health 1999;30:542-5.
53. Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997;26:1006-11.
54. Vrielink H, Reesink HW, van den Burg PJ, et al. Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients. Transfusion 1997;37:845-9.
55. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013;58:1918-29.
56. Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014;61:219-27.
57. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-13.
58. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet 2014;384:414-26.
59. An efficacy, pharmacokinetics, safety and tolerability study of TMC435 as part of a treatment regimen for hepatitis C-infected patients. no. NCT01725529. 2015. Available: https://clinicaltrials.gov/ct2/show/NCT01725529 (accessed 2016 Nov. 10).
60. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013;13:401-8.
61. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
62. Wei L, Han T, Yang D, et al. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naive patients in China and South Korea. J Gastroenterol Hepatol 2016;31:912-20.
63. Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014;60:741-7.
64. Scott J, Rosa K, Fu M, et al. Fatigue during treatment for hepatitis C virus: Results of self-reported fatigue severity in two phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2014;14:465.
65. Manns MP, Fried MW, Zeuzem S, et al. Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from phase IIb and III studies. J Viral Hepat 2015;22:366-75.
66. Yu M-L, Huang C-F. The unexpected high risk of occurrence or recurrence of hepatocellular carcinoma after successful antiviral therapy with interferonfree direct-acting antivirals. Transl Cancer Res 2016;5(Suppl 6):S1111-5.
67. Coffin PO, Stevens AM, Scott JD, et al. Patient acceptance of universal screening for hepatitis C virus infection. BMC Infect Dis 2011;11:160.
68. Myers RP, Crotty P, Town S, et al. Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study. CMAJ Open 2015;3:E62-7.
69. White DA, Anderson ES, Pfeil SK, et al. Differences between emergency nurse perception and patient reported experience with an ED HIV and hepatitis C virus screening program. J Emerg Nurs 2016;42:139-45.
70. Barocas JA, Brennan MB, Hull SJ, et al. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J 2014;11:1.
71. Norton BL, Voils CI, Timberlake SH, et al. Community-based HCV screening: knowledge and attitudes in a high risk urban population. BMC Infect Dis 2014; 14:74.
72. Zuure FR, Heijman T, Urbanus AT, et al. Reasons for compliance or noncompliance with advice to test for hepatitis C via an internet-mediated blood screening service: a qualitative study. BMC Public Health 2011;11:293.
73. Day CA, White B, Thein HH, et al. Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care 2008;20:116-23.
74. Vallabhaneni S, Macalino GE, Reinert SE, et al. Prisoners favour hepatitis C testing and treatment. Epidemiol Infect 2006;134:243-8.
75. Hepatitis C screening in Alberta: a health technology assessment. Calgary: The Health Technology Assessment Unit, University of Calgary; 2016. Available: www. health .alberta.ca/documents/AHTDP-HepatitisC-Screening-HTA-Report -2016.pdf (accessed 2016 Nov. 1).
76. A statement from the pan-Canadian Pharmaceutical Alliance. Toronto: Canada News Wire (CNW) Group Ltd.; 2017. Available: www.newswire.ca/news-releases/ a-statement-from-the-pan-canadian-pharmaceutical-alliance- 614373463.html (accessed 2017 Mar. 3).
77. Ontario Drug Benefit Formulary/Comparative Drug Index, edition 42. Toronto: Ontario Ministry of Health and Long-Term Care; 2017. Available: http://www.health. gov.on.ca/en/pro/programs/drugs/formulary42/summary-edition42-20170228. pdf (accessed 2017 Mar. 3).
78. Andrieux-Meyer I, Cohn J, de Araujo ES, et al. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob Health 2015;3:e676-7.
79. Payne E, Totten S, Archibald C. Hepatitis C surveillance in Canada. Can Commun Dis Rep 2014;40:421. Available: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/14vol40/dr-rm40-19/assets/pdf/14vol40-19-eng.pdf (accessed 2016 Nov. 1).
80. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 2013;66:726-35.
81. A study to characterize the epidemiology of hepatitis C infection in Canada, 2002: final report. Ottawa: Public Health Agency of Canada; 2004.
82. Wong T, Lee S. Hepatitis C: a review for primary care physicians. CMAJ 2006; 174:649-59.
83. Pepin J, Abou Chakra CN, Pepin E, et al. Evolution of the global burden of viral infections from unsafe medical injections, 2000-2010. PLoS One 2014;9:e99677.
84. Trubnikov M, Yan P, Njihia J, et al. Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): an age-period-cohort analysis. CMAJ Open 2014;2:E281-7.
85. Remis RS. Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada, 2007: final report. Ottawa: Public Health Agency of Canada; 2007. www.phac-aspc.gc.ca/sti-its-surv-epi/model/pdf/model07-eng.pdf (accessed 2016 Oct. 28).
86. Guidelines for the screening, care and treatment of persons with hepatitis C infection: updated version, April 2016. Geneva: World Health Organization; 2016. Available: www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016 (accessed 2016 Sept. 16).
87. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization; 2014. Available: www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en (accessed 2016 Sept. 16).
88. Hepatitis B and C testing: people at risk of infection. London (UK): National Institute for Health and Care Excellence; 2013. Available: www.nice.org.uk/ guidance/ph43 (accessed 2016 Nov. 10).
89. Management of hepatitis C. Edinburgh (UK): Scottish Intercollegiate Guidelines Network; 2013. Available: www.sign.ac.uk/pdf/sign133.pdf (accessed 2016 Sept. 16).
90. Operations directorate, health branch immigration medical examination instructions: hepatitis/liver disease. Ottawa: Citizenship and Immigration Canada; 2013. Available: www.cic.gc.ca/english/department/partner/pp/pdf/IMEI-Hepatitis.pdf (accessed 2016 Oct. 7).
91. Screening for hepatitis B and hepatitis C among ethnic minorities born outside the UK. London (UK): UK National Screening Committee; 2011. Available: https:// legacyscreening.phe.org.uk/hepatitis-ethnic (accessed 2016 Dec. 14).
92. Consensus recommendations for screening and diagnosis. Mulgrave (Australia): Gastroenterological Society of Australia; 2016. Available: http://www.hepcguidelines. org.au/consensus-recommendations/screening-and-diagnosis (accessed 2016 Sept. 16).
93. Pottie K, Greenaway C, Feightner J, et al. coauthors of the Canadian Collaboration for Immigrant and Refugee Health. Evidence-based clinical guidelines for immigrants and refugees. CMAJ 2011;183:E824-925.
94. Final recommendation statement - hepatitis C: screening. Rockville (MD): US Preventive Services Task Force; 2013. Available: www.uspreventiveservicestaskforce.org/ Page/Document/RecommendationStatementFinal/hepatitis-c-screening (accessed 2016 Sept. 16).
95. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998;47:1-39.
96. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945- 1965. MMWR Recomm Rep 2012;61:1-32.
97. Chou R, Cottrell EB, Wasson N, et al. Screening for hepatitis C virus infection in adults. Report No 12(13)-EHC090-EF. Rockville (MD): US Agency for Healthcare Research and Quality; 2012.
98. Moyer VA. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159:349-57.
99. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
100. Kimer N, Dahl EK, Gluud LL, et al. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open 2012;2:e001313.